nach oben

Clinical and Translational Oncology

Erschienen in:

01.09.2012 | Educational Series – Red Series*

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

verfasst von: Miriam López-Gómez, Paloma Cejas, María Merino, David Fernández-Luengas, Enrique Casado, Jaime Feliu

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Surgical resection remains the only option of cure for patients with colorectal liver metastases, and no patient should be precluded from surgery. There is much controversy not only regarding the most appropriate therapeutic approach in the neoadjuvant setting but also after surgery is performed. Many patients will experience early relapses but others will be long survivors. We need to establish reliable prognostic and predictive factors to offer a tailored treatment. Several prognostic factors after metastasectomy have been identified: high C-reactive protein levels, a high neutrophil–lymphocyte ratio, elevated neutrophil count and low serum albumin are related to a worst outcome. Elevated CEA and Ki 67 levels, intrahepatic and perihepatic lymph node invasion are also some of the markers related to a worst outcome. In contrast, the administration of preoperative chemotherapy has been associated with a better prognosis after hepatectomy. The administration of adjuvant chemotherapy should be done taking in consideration these factors. Regarding predictive factors, determination of ERCC1, TS, TP and DPD and UGT1 polymorphisms assessment could be considered prior to chemotherapy administration. This would avoid treatment related toxicities and increase this population quality of life.

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249PubMedCrossRef

Penna C, Nordlinger B (2002) Colorrectal metastases (liver and lung). Surg Clin North Am 82:1075–1090PubMedCrossRef

Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg 240:644–657PubMedCrossRef

Penna C, Nordlinger B (2002) Surgery of liver metastases from colorectal cancer: new promises. Br Med Bull 64:127–140PubMedCrossRef

Charnsangavej C, Clary B, Fong Y et al (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1261–1268PubMedCrossRef

Khatri VP, Nicholas J et al (2005) Extending the Frontier of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499PubMedCrossRef

Weber SM, Jarnagin WR, DeMatteo RP et al (2000) Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 7:643–650PubMedCrossRef

Parks R, Gonen M, Kemeny N et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–761PubMedCrossRef

Figueras J, Torras J, Valls C et al (2007) Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 50:478–488PubMedCrossRef

10.

Wang X, Hershman DL, Abrams JA et al (2007) Predictors of survival after hepatic resection among patients with colorectal liver metastases. Br J Cancer 97:1606–1612PubMedCrossRef

11.

Adam R, Bhangui P, Poston G (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774–787PubMedCrossRef

12.

Langer B, Bleiberg H, Labianca R et al (2002) Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 21(suppl):149a (abstr 592)

13.

Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: fFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982PubMedCrossRef

14.

Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911PubMedCrossRef

15.

Ychou M, Hohenberger W, Thezenas S et al (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:1964–1970PubMedCrossRef

16.

Kanemitsu Y, Kato T, Shimizu Y et al (2009) A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastases from colorectal cancer. Japan Clinical Oncology Group study JCOG0603. Jpn J Clin Oncol 39:406–409PubMedCrossRef

17.

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016PubMedCrossRef

18.

Asahara T, Kikkawa M, Okajima M et al (1998) Studies of postoperative transarterial infusion chemotherapy for liver metastases of colorectal carcinoma after hepatectomy. Hepatogastroenterology 45:805–811PubMed

19.

Kemeny MM, Adak S, Gray B et al (2002) Combined modality treatment for resectable metastastatic colorectal carcinoma to the liver. Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 20:1499–1505PubMedCrossRef

20.

Lorenz M, Muller HH, Schramm H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5 fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756–762PubMedCrossRef

21.

Lygidakis NJ, Ziras N, Parissis J (1995) Resection versus resection combined with adjuvant pre and post-operative chemotherapy immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42:155–161PubMed

22.

Rudroff C, Altendorf-Hoffmann A, Stangl R et al (1999) Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 384:243–249PubMedCrossRef

23.

Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048PubMedCrossRef

24.

Kemeny NE, Gonen M (2005) Hepatic arterial infusion after liver resection. N Engl J Med 352:734–735PubMedCrossRef

25.

Ito H, Are C, Gonen M et al (2008) Effect of postoperative morbidity on long term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:994–1002PubMedCrossRef

26.

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRef

27.

Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognosis scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie”. Cancer 77:1254–1262PubMedCrossRef

28.

Robertson DJ, Stukel TA, Gottlieb DJ et al (2009) Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 115:752–759PubMedCrossRef

29.

Aldrighetti L, Castoldi R, Di Palo S et al (2005) Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases. Chir Ital 57:555–570PubMed

30.

Schindl M, Wigmore SJ, Currie EJ (2005) Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 140:183–189PubMedCrossRef

31.

Lise M, Bacchetti S, Da Pian P (2001) Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg 25:638–644PubMedCrossRef

32.

Iwatsuki S, Dvorchik I, Madariaga JR et al (1999) Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a scoring system. J Am Coll Surg 189:291–299PubMedCrossRef

33.

Ueno H, Mochizuki H, Hatsuse K (2000) Indicators for treatment strategies of colorectal liver metastases. Ann Surg 231:59–66PubMedCrossRef

34.

Gayowski TJ, Iwatsuki S, Madariaga JR et al (1994) Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116:703–710PubMed

35.

Mullen JT, Ribero D, Reddy SK et al (2007) Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204:854–862PubMedCrossRef

36.

Vibert E, Bretagnol F, Arnaud Alves et al (2007) Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable metastases. Dis Colon Rectum 50:1776–1782PubMedCrossRef

37.

Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognosis variables for asymptomatic patients. J Am Coll Surg 196:722–728PubMedCrossRef

38.

Kuo IJ, Leu SY, Liu MC et al (2003) How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum 46:1646–1652PubMedCrossRef

39.

Rosen SA, Buell JF, Yoshida A et al (2000) Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 135:530–534PubMedCrossRef

40.

Tamandl D, Gruenberger B, Herberger B (2009) Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol 100:364–371PubMedCrossRef

41.

O′Riordain MG, Falconer JS, Maingay J et al (1999) Peripheral blood cells from weight losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol 15:823–827PubMed

42.

Lamb GW, McMillan DC, Ramsey S et al (2006) The relationship between the preoperative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 94:781–784PubMedCrossRef

43.

Zahlten-Hinguranage A, Goldschmidt H, Cremer FW et al (2006) Preoperative elevation of serum C reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer 95:782–787PubMedCrossRef

44.

Schmidt H, Suciu S, Punt CJ et al (2007) Pretreatment levels of peripheral neutrophils and leucocytes as independent predictors of overall survival in patients with American joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotheraphy trial. J Clin Oncol 25:1562–1569PubMedCrossRef

45.

Neal CP, Mann CD, Sutton CD et al (2009) Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with respectable colorectal liver metastases. Eur J Cancer 45:56–64PubMedCrossRef

46.

Wong VK, Malik HZ, Hamady ZZ et al (2007) C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 96:22–25CrossRef

47.

Malik HZ, Prasad KR, Halazum KJ et al (2007) Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246:806–814PubMedCrossRef

48.

Atzpodien J, Royston P, Wandert T et al (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88:348–353PubMedCrossRef

49.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

50.

Aoyagi Y, Oda T, Kinoshita T et al (2004) Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br J Cancer 91:1316–1326PubMedCrossRef

51.

Nozawa H, Chiu C, Hanagan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103:12493–12498PubMedCrossRef

52.

Ardi VC, Kupriyanova TA, Deryugina EI et al (2007) Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267PubMedCrossRef

53.

Franch- Arcas G (2001) The meaning of hypoalbuminemia in clinical practice. Clin Nutr 20:265–269PubMedCrossRef

54.

Argiles JM, Busquets S, Lopez Soriano FJ (2006) Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 130:199–217PubMedCrossRef

55.

Ishizuka M, Nagata H, Takagi K et al (2007) Inflammation based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 246:1047–1051PubMedCrossRef

56.

Dixon MR, Haukoos JS, Udani SM et al (2003) Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 138:962–966PubMedCrossRef

57.

Arru M, Aldrighetti L, Castoldi R et al (2008) Analysis of prognostic factors influencing long-term survival alter hepatic resection for metastatic colorectal cancer. World J Surg 32:93–103PubMedCrossRef

58.

Corsi DC, Ciaparrone M, Zannoni G et al (2002) Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 38:527–534PubMedCrossRef

59.

Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 91:327–333PubMedCrossRef

60.

Ishizuka D, Shirai Y, Sakai Y et al (2001) Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19–9 levels. Int J Colorectal Dis 16:32–37PubMedCrossRef

61.

Berger AC, Sigurdson ER, LeVoyer T et al (2005) Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23:8706–8712PubMedCrossRef

62.

Noura S, Ohue M, Kano S et al (2010) Impact of metastatic lymph node ratio in node-positive colorectal cancer. Word J Gastrointest Surg 2:70–77CrossRef

63.

Manxhuka-Kerliu S, Telaku S, Ahmetaj H et al (2009) Colorectal cancer: prognostic values. Bosn J Basic Med Sci. 9:19–24PubMed

64.

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef

65.

Kajiyama K, Maeda T, Takenaka K et al (1999) The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of scirrhous-type and nonscirrhous type growth. Am J Surg Pathol 23:892–902PubMedCrossRef

66.

Sasaki A, Aramaki M, Kawano K et al (2002) Prognostic significance of intrahepatic lymphatic invasion in patients with hepatic resection due to metastases from colorectal carcinoma. Cancer 95:1CrossRef

67.

Bockhorm M, Sotiropoulos G, Neuhaus J et al (2009) Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases. Int J Colorectal Dis 24:845–850CrossRef

68.

Korita PV, Wakai T, Shirai Y (2007) Intrahepatic lymphatic invasion independently predicts poor survival and recurrences after hepatectomy in patients with colorectal carcinoma liver metastases. Ann Surg Oncol 14:3472–3480PubMedCrossRef

69.

Bennett JJ, Schmidt CR, Klimstra DS et al (2008) Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol 15:1130–1136PubMedCrossRef

70.

Elias DM, Ouellet JF (2003) Incidence, distribution and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin North Am 12:221–229CrossRef

71.

Jaeck D (2003) The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 10:1007–1011PubMedCrossRef

72.

Laurent C, Sa Cunha A, Rullier E et al (2006) Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastases. J Am Coll Surg 198:884–891CrossRef

73.

Fuhrman GM, Curley SA, Hohn DC et al (1995) Improved survival after resection of colorectal liver metastases. Ann Surg Oncol 2:537–541PubMedCrossRef

74.

Kokudo N, Sato T, Seki M et al (1999) Hepatic lymph node involvement in resected cases of liver metastases from colorectal cancer. Dis Colon Rectum 42:1285–1290PubMedCrossRef

75.

Rodgers MS, McCall JL (2000) Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87:1142–1155PubMedCrossRef

76.

Oussoultzoglou E, Romain B, Panaro F et al (2009) Long term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Surg 249:879–886PubMedCrossRef

77.

Kokudo N, Miki Y, Sugai S et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma. Arch Surg 137:833–840PubMedCrossRef

78.

Hamady ZZR, Cameron IC, Wyatt J et al (2006) Resection margin in patients undergoing hepatectomy for colorectal liver metastases: a critical appraisal of the 1 cm rule. Eur J Surg Oncol 32:557–563PubMedCrossRef

79.

Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–724PubMedCrossRef

80.

Wray CJ, Lowy Am, Mathews JB et al (2005) The significance and clinical factors associated with a subcentimeter resection of colorectal liver metastases. Ann Surg Oncol 12:1–7CrossRef

81.

Nuzzo G, Giuliante F, Ardito F et al (2008) Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single center experience. Surgery 143:384–393PubMedCrossRef

82.

Are C, Gonen M, Zazzali K et al (2007) The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 246:295–300PubMedCrossRef

83.

De Jong Mc, Pulitano C, Ribero D et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440–448PubMed

84.

Elias D, Cavalcanti A, Sabourin JC et al (1998) Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 69:88–93PubMedCrossRef

85.

Jaeck D, Bachellier P, Guiguet M et al (1997) Long term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 84:977–980PubMedCrossRef

86.

Kato T, Yasui K, Hirai T et al (2003) Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46:S22–S31PubMed

87.

Konopke R, Kersting S, Makowiec F et al (2008) Resection of colorectal liver metastases: is a resection margin of 3 mm enough? A multicenter analysis of the GAST study group. World J Surg 32:2047–2056PubMedCrossRef

88.

Felice G, Ardito F, Vellone M et al (2009) Role of the surgeon as a variable in long term survival after liver resection for colorectal metastases. J Surg Oncol 100:538–545CrossRef

89.

Bodingbauer M, Tamandl D, Schmid K et al (2007) Size of surgical margin does not influence recurrence rates after curarive liver resection for colorectal cancer liver metastases. Br J Surg 94:1133–1138PubMedCrossRef

90.

Belli G, D’Agostino A, Ciciliano F et al (2002) Liver resection for hepatic metastases: 15 years of experience. J Hepatobiliary Pancreat Surg 9:607–613PubMedCrossRef

91.

Ming-Shian T, Yen Hao S, Ming-Chih H (2007) Clinicopathological features and prognosis in respectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14:786–794CrossRef

92.

Bockhorn M, Frilling A, Frühhauf NR et al (2008) Survival of patients with synchronous and metachronous colorectal liver metastases—is there a difference? J Gastrointest Surg 12:1399–1405PubMedCrossRef

93.

Van der Pool AE, Lalmahomed ZS, Ozbay Y et al (2009) “Staged” liver resection in synchronous and metachronous colorectal hepatic metastases; differences in clinicopathological features and outcome. Colorectal Dis Nov 14 [Epub ahead of print]

94.

Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985–992PubMedCrossRef

95.

Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastasis. Correlation between tumour response and resection rates. Ann Oncol 16:311–1319CrossRef

96.

Alberts SR, Horvath WL, Sternfeld WC et al (2005) Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol 23:1–7CrossRef

97.

Barone C, Nuzzo G, Cassano A et al (2007) Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97:1035–1039PubMedCrossRef

98.

Bokemeyer C, Staroslawska E, Makhson A et al (2007) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. Eur J Cancer Suppl 5:4CrossRef

99.

Van Cutsem E, Lang I, D’haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cance (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26 (Abstr 2)

100.

Folprecht G, Gruenberger T, Hartmann JT et al (2008) Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CLM). Ann Oncol 19:viii168 (Abstr 510PD)

101.

Saltz LB, Clarke S, Díaz Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRef

102.

Gallagher DJ, Zheng J, Capanu M et al (2009) Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 16:1844–1851PubMedCrossRef

103.

Kemeny NE, Capanu M, Huitzil-Melendez D et al (2007) Is neoadjuvant treatment necessary prior to liver resection in patients with respectable liver metastasis from colorectal carcinoma treated with post-resection hepatic arterial infusion plus systemic chemotherapy? J Clin Oncol 25:625s (suppl; abstr 14503

104.

Gruenberger B, Scheithauer W, Punzengruber R et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120PubMedCrossRef

105.

Chiappa A, Bertani E, Makuuchi M (2009) Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology 56:829–834PubMed

106.

Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064PubMedCrossRef

107.

Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635–1641PubMedCrossRef

108.

Kornprat P, Jarnagin WR, Gonen M et al (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151–1160PubMedCrossRef

109.

Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastastic colorectal cancer. J Clin Oncol 26:1830–1835PubMedCrossRef

110.

Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12:5268–5272PubMedCrossRef

111.

Finkelstein SD, Sayegh R, Bakker A et al (1993) Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128:526–532PubMedCrossRef

112.

Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al (2001) Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. Br J Cancer 85:692–696PubMedCrossRef

113.

Richman SD, Seymour MT, Chambers P et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results frome de MRF FOCUS trial. J Clin Oncol 27:5931–5937PubMedCrossRef

114.

Nash GM, Gimbel M, Shia J et al (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17:572–578PubMedCrossRef

115.

Saridaki Z, Papadatos-Pastos D et al (2010) BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. Br J Cancer 102:1762–1768PubMedCrossRef

116.

Brown DC, Gatter KC (1990) Monoclonal antibody Ki 67: its use in histopathology. Histopathology 17:489–503PubMedCrossRef

117.

Zolzer F, Speer A, Pelzer T et al (1995) Evidence for quiescent S and G2-phase cells in human colorectal carcinomas: a flow cytometric study with the Ki-67 antibody. Cell Prolif 28:313–317PubMedCrossRef

118.

Finlay IG, Meek D, Brunton F (1988) Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 75:641–644PubMedCrossRef

119.

Petrowsky H, Sturm I, Graubitz O et al (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. EJSO 27:80–87PubMedCrossRef

120.

Costa A, Doci R, Mochen C et al (1997) Cell proliferation related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 15(2008):14

121.

Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 315:453–455CrossRef

122.

Hartwell L (1992) Deffects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543–546PubMedCrossRef

123.

Adrover E, Maestro ML, Sanz-Casla MT et al (1999) Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer 81:122–126PubMedCrossRef

124.

Starzynska T, Bromley M, Marlicz K et al (1997) Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepatol 9:183–186PubMedCrossRef

125.

Lotter O, Amr A, Safi F (2010) Prognostic significance of p53-expression in colorectal carcinoma as measured by a luminometric immunoassay Ger Med Sci. 8:Doc 24

126.

Hsieh JS, Lin SR, Chang MY et al (2005) APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 71:336–343PubMed

127.

De Jong KP, Gouw ASH, Peeters PMJG et al (2005) P53 mutation analysis on colorectal liver metastases: relation to actual survival, angiogenic status and p53 overexpression. Clin Cancer Res 11:11

128.

Russo A, Migliavacca M, Bazan V et al (1998) Prognostic significance of proliferative activity, DNA ploidy, p53 and Ki-ras mutations in colorectal liver metastases. Cell Prolif 31:139–153PubMedCrossRef

129.

De Jong KP, Stellema R, Karrembeld A et al (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p 53 and Ki 67 in colorectal liver metastases and corresponging primary tumors. Hepatology 28:971–979PubMedCrossRef

130.

Pocard M, Paradis V, Adam R et al (1998) Possible prognostic significance of p53 immunoreactive status of hepatic colorectal cancer metastases following surgical resection. Eur J Cancer 34:594–595PubMedCrossRef

131.

Tullo A, D’Erchia AM, Honda K et al (1999) Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res 5:3523–3528PubMed

132.

Crowe PJ, Phil D, Yang JL et al (2001) Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 25:996–1001PubMedCrossRef

133.

Yang Y, Forslund A, Remotti H et al (2001) p53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91:727–736PubMedCrossRef

134.

Greider CW (1991) Telomeres. Curr Opin Cell Biol 3:444–451PubMedCrossRef

135.

Shoji Y, Yoshinaga K, Inoue A et al (2000) Quantification of telomerase activity in sporadic colorectal carcinoma: association with tumor growth and venous invasion. Cancer 88:1304–1309PubMedCrossRef

136.

Wei R, Younes M (2002) Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa. Hum Pathol 33:693–696PubMedCrossRef

137.

Smith DL, Soria JC, Morat L et al (2004) Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 11:45–51PubMedCrossRef

138.

Dômont J, Pawlik TM, Boige V (2005) Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 23:3086–3093PubMedCrossRef

139.

Kim SY, Kim HJ, Hong YS et al (2009) Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol 100:713–718PubMedCrossRef

140.

Cunningham D, Humblet Y, Siena S, Khayat D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef

141.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 351:337–345CrossRef

142.

Johnston PG, Lenz HJ, Leichman CG et al (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412PubMed

143.

Cascinu S, Graziano F, Valentini M et al (2001) Vascular endothelial growth factor expression. S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239–244PubMedCrossRef

144.

Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22:529–536PubMedCrossRef

145.

Etienne MC, Chazal M, Laurent-Puig P et al (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20:2832–2843PubMedCrossRef

146.

Bathe OF, Franceschi D, Livingstone AS et al (1999) Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5:34–40PubMed

147.

Yamada H, Ichikawa W, Uetake H (2001) Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer 169–173

148.

Jonhston PG, Benson AB, Catalano P et al (2003) Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21:815–819CrossRef

149.

Findlay MP, Cunningham G, Morgan S et al (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903–909PubMedCrossRef

150.

Lansiaux A, Bras-Goncalves RA, Rosty C et al (2001) Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CPT-11. Anticancer Res 21:471–476PubMed

151.

Paradiso A, Xu J, Mangia A et al (2004) Topoisomerase I thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111(2):252–258PubMedCrossRef

152.

Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–237PubMedCrossRef

153.

Lyss AP, Lilenbaum RC, Harris BE, Diasio RB (1993) Severe 5 fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11:239–240PubMedCrossRef

154.

Milano A, Etienne MC, Pierrefite V et al (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627–630PubMedCrossRef

155.

Kobayashi N, Kubota T, Watanabe M et al (1999) Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5 fluorouracil, respectively. J Infect Chemother 5:144–148PubMedCrossRef

156.

Tsuji T, Sawai T, Takeshita H et al (2004) Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54:531–536PubMedCrossRef

157.

van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950PubMedCrossRef

158.

Okumura K, Shiomi H, Mekata E et al (2006) Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastases of colorectal cancer. Oncol Rep 15:875–882PubMed

159.

Johnston PG, Kaye S (2001) Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12:639–646PubMedCrossRef

160.

Cao D, Russell RL, Zhang D et al (2002) Uridine phosphorylase (−/−) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62:2313–2317PubMed

161.

Nishimura G, Terada I, Kobayashi T et al (2002) S. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effectos of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9:479–482PubMed

162.

Humerickhouse R, Lohrbach K, Li L et al (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189–1192PubMed

163.

Fuchs CS (2003) Current and ongoing trials with irinotecan in the United States. Semin Oncol 30:9–17PubMedCrossRef

164.

Iyer L, Das S, Janish L et al (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43–47PubMedCrossRef

165.

Marcuello E, Altés A, Menoyo A et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678–682PubMed

166.

Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48:265–277PubMedCrossRef

167.

Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin and bis-aceto-ammine-dichlorocyclohexylamine-platinum (IV) (JM 216) platinum intrastrand DNA diadducts. Cancer Res 59:3968–3971PubMed

168.

Metzger R, Leichman CG, Danenberg KD et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309–316PubMed

169.

Shirota Y, Stoehlmacher J, Brabender J et al (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMed

170.

Park DJ, Zhang W, Stoehlmacher J et al (2003) ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162–166PubMed

171.

Park DJ, Stoehlmacher J, Zhang W et al (2001) A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654–8658PubMed

172.

Stoehlmacher J, Park DJ, Zhang W et al (2002) Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942PubMedCrossRef

173.

Nordlinger B, Van Cutsem E, Rougier P et al (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43:2037–2045PubMedCrossRef

174.

Van Cutsem E, Nordlinger B, Adam R et al (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221PubMedCrossRef

175.

Deenen M, Tol J, Burylo AM (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17:3455–3468PubMedCrossRef

176.

Paseto LM, D’Andrea MR et al (2006) Oxaliplatin-related neuropathy: why and when? Crit Rev Oncol Hematol 59:159–168CrossRef

177.

www.clinicaltrials.gov, NCT00268398

178.

Ta J, Artru P, Paye F et al (2005) Intensive chemotherapy combined with surgery for metastastatic colorectal cancer: results from a phase II study. J Clin Oncol 23:502–509

179.

Wilson PM, Ladner RD, Lenz HJ (2007) Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res 1:237–246PubMed

Titel: Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?
verfasst von: Miriam López-Gómez
Paloma Cejas
María Merino
David Fernández-Luengas
Enrique Casado
Jaime Feliu
Publikationsdatum: 01.09.2012
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 9/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0853-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

In answer to: “Comments to SEOM clinical guidelines for the treatment of thyroid cancer” by Garcilaso Riesco-Eizaguirre et al

Comments to SEOM clinical guidelines for the treatment of thyroid cancer

Trends in the lung cancer incidence and mortality in the Slovak and Czech Republics in the contexts of an international comparison

Searching for Hif1-α interacting proteins in renal cell carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie